Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment;Elvitegravir/cobicistat/emcitrabine/ténofovir disoproxil (fumarate de) en association dans un seul comprimé pour le traitement de l'infection par le VIH

Annals of Pharmacotherapy

Volumn 46, Issue 12, 2012, Pages 1671-1677

  Olin, Jacqueline L ^a   Spooner, Linda M ^b   Klibanov, Olga M ^a  

^a WINGATE UNIVERSITY   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Antiretroviral therapy; Cobicistat; Elvitegravir; Emtricitabine; HIV; Stribild tenofovir

Indexed keywords

ALFUZOSIN; AMIODARONE; ATAZANAVIR PLUS RITONAVIR; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CARBAMAZEPINE; CISAPRIDE; CLARITHROMYCIN; CLONAZEPAM; COBICISTAT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DEXAMETHASONE; DIGOXIN; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FLUTICASONE; KETOCONAZOLE; MEVINOLIN; MIDAZOLAM; PIMOZIDE; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; SALMETEROL; SILDENAFIL; SIMVASTATIN; TRIAZOLAM; UNINDEXED DRUG;

ABNORMAL DREAMING; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TREATMENT FAILURE; EYE JAUNDICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTRANSAMINASEMIA; INSOMNIA; KIDNEY DISEASE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT DISEASE;

ADENINE; ANTI-HIV AGENTS; CARBAMATES; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; DRUG COMBINATIONS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; ORGANOPHOSPHONATES; QUINOLONES; TABLETS; THIAZOLES; VIRAL LOAD;

EID: 84872253325     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R468     Document Type: Review

References (19)

1. National Institutes of Health: Department of Health and Human Services. HIV/AIDS Quick facts: global. March 2011. http://www.niaid.nih.gov/topics/HIVAIDS/Understanding/Pages/quickFacts.aspx (accessed 2012 Sep 18).
2. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. March 27, 2012. http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/aa_recommendations.pdf (accessed 2012 Sep 18).
3. Package insert. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir). Foster City, CA: Gilead Sciences, August 2012.
4. Package insert. Emtriva (emtricitabine). Foster City, CA: Gilead Sciences, July 2012.
5. Package insert: Viread (tenofovir). Foster City, CA: Gilead Sciences, August 2012.
6. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naïve and treatment-experienced patients. J Acquir Immune Defic Syndr 2006;43:1-5.
7. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharm Ther 2010;87:322-9.
8. Ramanathan S, Shen G, Hinkle J, Enejosa J, Kearney BP. Pharmacokinetic evaluation of drug interactions with ritonavir-boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid reducing agents (abstract 69). Presented at: 8th International Workshop on Clinical Pharmacology of HIV Therapy; Budapest, Hungary; April 16-18, 2007.
9. Mathias A, Koziara J, Wei L, Warren D, Kearney BP. Effect of acid reducing agents on the relative bioavailability and pharmacokinetics of cobicistat boosted elvitegravir (abstract P13). Presented at: 12th International Workshop on Clinical Pharmacology of HIV Therapy; Miami, FL; April 13-15, 2011.
10. Mathias A, Jain A, Hui J, Shen G, Kearney BP. Pharmacokinetic characterization of GS-9137, an HIV integrase inhibitor dosed with ritonavir (abstract 75). Presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy; April 20-22, 2006; Lisbon, Portugal.
11. German P, Warren D, West S, Hui J, Kearney BP. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010;55:323-9.
12. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012;379:2439-48.
13. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavirboosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012;379:2429-38.
14. Garrido C, Villacian J, Zahonero N, et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother 2012;56:2873-8.
15. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011;25:F7-12.
16. German P, Lui C, Warren D, et al. Effect of cobicistat on glomerular filtration rate (GFR) in subjects with normal and impaired renal function (abstract H2-804). Presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; September 17-20, 2011.
17. Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus ritonavir each with atazanavir plus fixed-dose emtricitabine/tenofovir DF in the initial treatment of HIV infection. AIDS 2011;25:1881-6.
18. Department of Health and Human Services. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents recommends a fixed-dose combination product of elvitegravir/cobicistat/tenofovir/emtricitabine as an alternative regimen in antiretroviral treatment-naïve individuals with HIV-1 infection. September 18, 2012. http://aidsinfo.nih.gov/contentfiles/AdultARVStatementOnEVG_COBI_TDF_FTC.pdf (accessed 2012 Oct 31)
19. Red book. Ann Arbor, MI: Thomson Reuters, 2012.